These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 21792529)

  • 81. Association Between Antipsychotic Medication Use and Diabetes.
    Holt RIG
    Curr Diab Rep; 2019 Sep; 19(10):96. PubMed ID: 31478094
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Metabolic issues in psychotic disorders with the focus on first-episode patients: a review.
    Britvic D; Maric NP; Doknic M; Pekic S; Andric S; Jasovic-Gasic M; Popovic V
    Psychiatr Danub; 2013 Dec; 25(4):410-5. PubMed ID: 24247054
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Weight gain--as possible predictor of metabolic syndrome.
    Grahovac T; Ružić K; Dadić-Hero E; Sepić-Grahovac D; Sabljić V
    Psychiatr Danub; 2011 Mar; 23(1):105-7. PubMed ID: 21448110
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study.
    Kivimäki M; Hamer M; Batty GD; Geddes JR; Tabak AG; Pentti J; Virtanen M; Vahtera J
    Diabetes Care; 2010 Dec; 33(12):2611-6. PubMed ID: 20823343
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
    Meco G; Bernardi S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):311-3. PubMed ID: 16919377
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder.
    Wong MM; Chen EY; Lui SS; Tso S
    Clin Schizophr Relat Psychoses; 2011 Oct; 5(3):135-41. PubMed ID: 21983497
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.
    Nwosu BU; Meltzer B; Maranda L; Ciccarelli C; Reynolds D; Curtis L; King J; Frazier JA; Lee MM
    J Pediatr Endocrinol Metab; 2011; 24(9-10):619-26. PubMed ID: 22145446
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Type 2 diabetes in children and adolescents on atypical antipsychotics.
    Pramyothin P; Khaodhiar L
    Curr Diab Rep; 2015 Aug; 15(8):53. PubMed ID: 26084582
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.
    Verhaegen AA; Van Gaal LF
    Curr Obes Rep; 2021 Mar; 10(1):1-13. PubMed ID: 33400222
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Predicting antidepressive treatment success--critical review and perspectives].
    Schmauss M; Erfurth A
    Fortschr Neurol Psychiatr; 1993 Aug; 61(8):274-83. PubMed ID: 8375794
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment.
    Farahani A; Correll CU
    J Clin Psychiatry; 2012 Apr; 73(4):486-96. PubMed ID: 22579147
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
    Deng C
    Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Drugs for psychiatric disorders.
    Med Lett Drugs Ther; 1989 Feb; 31(786):13-20. PubMed ID: 2563894
    [No Abstract]   [Full Text] [Related]  

  • 94. Are the atypical antipsychotic drugs antidepressants?
    Parker G; Malhi G
    J Clin Psychopharmacol; 2002 Feb; 22(1):94-5. PubMed ID: 11799351
    [No Abstract]   [Full Text] [Related]  

  • 95. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
    Alméras N; Després JP; Villeneuve J; Demers MF; Roy MA; Cadrin C; Mottard JP; Bouchard RH
    J Clin Psychiatry; 2004 Apr; 65(4):557-64. PubMed ID: 15119921
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Psychotropic drugs].
    Müller-Spahn F
    Ther Umsch; 1999 Dec; 56(12):719-25. PubMed ID: 10638279
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Metabolic issues in patients with severe mental illness.
    Citrome L; Blonde L; Damatarca C
    South Med J; 2005 Jul; 98(7):714-20. PubMed ID: 16108240
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Antidepressive agents in the elderly].
    de Hooge JK
    Tijdschr Gerontol Geriatr; 1990 Dec; 21(6):259-67. PubMed ID: 1980385
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Lipogenic effects of psychotropic drugs: focus on the SREBP system.
    Ferno J; Skrede S; Vik-Mo AO; Jassim G; Le Hellard S; Steen VM
    Front Biosci (Landmark Ed); 2011 Jan; 16(1):49-60. PubMed ID: 21196158
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Drug-induced metabolic syndrome.
    Wofford MR; King DS; Harrell TK
    J Clin Hypertens (Greenwich); 2006 Feb; 8(2):114-9. PubMed ID: 16470080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.